BioStock: Restart for Chordate Medical's migraine study

Yesterday, Chordate Medical announced that the company’s migraine study has resumed in Finland after being paused for a number of months due to the Covid-19 pandemic. The goal is now to complete the migraine study in July so that Chordate Medical’s method can be CE marked as a treatment for chronic migraine.

Read the full article at biostock.se:

https://www.biostock.se/en/restart-for-chordate-medicals-migraine-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se